Antitope to Present at DDT, Boston, USA; August 7 2008
Dr. Matthew Baker, CSO of Antitope, will be presenting a workshop entitled ‘Immunogenicity Prediction for New Biologis' at this year's Drug Discovery and Development of Innovative Therapeutics Conference in Boston.
The workshop will discuss, the critical question: How can the potential risk of immunogenicity be assessed before new biologics enter the clinic? The session will illustrate a variety of techniques for immunogenicity predictions, provide an overview of tools and technologies currently available to pre-determine immunogenicity, illustrate techniques for salvaging immunogenic therapeutics and provide case studies of applications in oncology, autoimmune diseases, vaccine development and other areas.
For more information, visit the conference website at http://www.drugdisc.com/